Investigation in Progress — No Complaint Filed Yet
BG&G is actively investigating potential securities fraud claims against Medline Inc.. If a complaint is filed, this page will be updated. Investors are encouraged to contact us now to preserve their rights.
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Medline Inc. (“Medline” or “the Company”) (NASDAQ: MDLN). Investors who purchased Medline securities are encouraged to obtain additional information and assist the investigation.
The investigation concerns whether Medline has violated federal securities laws.
Medline Investigation Details
On June 3, 2026, Medline is the subject of a report published by Reuters titled: “Medline draws another US FDA warning in two months over quality lapses.” According to the article, “The Food and Drug Administration, in its letter dated May 28, said the company failed to thoroughly investigate microbial contamination incidents in finished drug products and also cited inadequate cleaning practices.” Following this news, Medline’s stock price dropped.
What’s Next for Medline Investors?
If you are aware of any facts relating to this investigation or purchased Medline securities, you can assist this investigation. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 917-590-0911
MDLN — Stock Performance
About Bronstein, Gewirtz & Grossman, LLC
We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
“Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace.”